Progesterone receptor isoform ratio: a breast cancer prognostic and predictive factor for antiprogestin responsiveness

<b>Background:</b> Compelling evidence shows that progestins regulate breast cancer growth. Using preclinical models, we demonstrated that antiprogestins are inhibitory when the level of progesterone receptor isoform A (PR-A) is higher than that of isoform B (PR-B) and that they might st...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Rojas, Paola A., May, María, Sequeira, Gonzalo R., Elia, Andrés, Alvarez, Michelle, Martínez, Paula, González, Pedro Horacio, Hewitt, Stephen, He, Xiaping, Perou, Charles M., Molinolo, Alfredo, Gibbons, Luz, Abba, Martín Carlos, Gass, Hugo, Lanari, Claudia
Formato: Articulo
Lenguaje:Inglés
Publicado: 2017
Materias:
Acceso en línea:http://sedici.unlp.edu.ar/handle/10915/87477
Aporte de:
id I19-R120-10915-87477
record_format dspace
institution Universidad Nacional de La Plata
institution_str I-19
repository_str R-120
collection SEDICI (UNLP)
language Inglés
topic Ciencias Médicas
breast cancer
progesterone receptor isoform
molecular characteristics
clinical characteristics
spellingShingle Ciencias Médicas
breast cancer
progesterone receptor isoform
molecular characteristics
clinical characteristics
Rojas, Paola A.
May, María
Sequeira, Gonzalo R.
Elia, Andrés
Alvarez, Michelle
Martínez, Paula
González, Pedro Horacio
Hewitt, Stephen
He, Xiaping
Perou, Charles M.
Molinolo, Alfredo
Gibbons, Luz
Abba, Martín Carlos
Gass, Hugo
Lanari, Claudia
Progesterone receptor isoform ratio: a breast cancer prognostic and predictive factor for antiprogestin responsiveness
topic_facet Ciencias Médicas
breast cancer
progesterone receptor isoform
molecular characteristics
clinical characteristics
description <b>Background:</b> Compelling evidence shows that progestins regulate breast cancer growth. Using preclinical models, we demonstrated that antiprogestins are inhibitory when the level of progesterone receptor isoform A (PR-A) is higher than that of isoform B (PR-B) and that they might stimulate growth when PR-B is predominant. The aims of this study were to investigate ex vivo responses to mifepristone (MFP) in breast carcinomas with different PR isoform ratios and to examine their clinical and molecular characteristics. <b>Methods:</b> We performed human breast cancer tissue culture assays (n = 36) to evaluate the effect of MFP on cell proliferation. PR isoform expression was determined by immunoblotting (n = 282). Tumors were categorized as PRA-H (PR-A/PR-B ≥ 1.2) or PRB-H (PR-A/PR-B ≤ 0.83). RNA was extracted for Ribo-Zero-Seq sequencing to evaluate differentially expressed genes. Subtypes and risk scores were predicted using the PAM50 gene set, the data analyzed using The Cancer Genome Atlas RNA-seq gene analysis and other publicly available gene expression data. Tissue microarrays were performed using paraffin-embedded tissues (PRA-H n = 53, PRB-H n = 24), and protein expression analyzed by immunohistochemistry. All statistical tests were two-sided. <b>Results:</b> One hundred sixteen out of 222 (52.3%) PR+ tumors were PRA-H, and 64 (28.8%) PRB-H. Cell proliferation was inhibited by MFP in 19 of 19 tissue cultures from PRA-H tumors. A total of 139 transcripts related to proliferative pathways were differentially expressed in nine PRA-H and seven PRB-H tumors. PRB-H and PRA-H tumors were either luminal B or A phenotypes, respectively (P =.03). PRB-H cases were associated with shorter relapse-free survival (hazard ratio [HR] = 2.70, 95% confidence interval [CI] = 1.71 to 6.20, P =.02) and distant metastasis-free survival (HR = 4.17, 95% CI = 2.18 to 7.97, P <.001). PRB-H tumors showed increased tumor size (P <.001), Ki-67 levels (P <.001), human epidermal growth factor receptor 2 expression (P =.04), high grades (P =.03), and decreased total PR (P =.004) compared with PRA-H tumors. MUC-2 (P <.001) and KRT6A (P =.02) were also overexpressed in PRB-H tumors. <b>Conclusion:</b> The PRA/PRB ratio is a prognostic and predictive factor for antiprogestin responsiveness in breast cancer.
format Articulo
Articulo
author Rojas, Paola A.
May, María
Sequeira, Gonzalo R.
Elia, Andrés
Alvarez, Michelle
Martínez, Paula
González, Pedro Horacio
Hewitt, Stephen
He, Xiaping
Perou, Charles M.
Molinolo, Alfredo
Gibbons, Luz
Abba, Martín Carlos
Gass, Hugo
Lanari, Claudia
author_facet Rojas, Paola A.
May, María
Sequeira, Gonzalo R.
Elia, Andrés
Alvarez, Michelle
Martínez, Paula
González, Pedro Horacio
Hewitt, Stephen
He, Xiaping
Perou, Charles M.
Molinolo, Alfredo
Gibbons, Luz
Abba, Martín Carlos
Gass, Hugo
Lanari, Claudia
author_sort Rojas, Paola A.
title Progesterone receptor isoform ratio: a breast cancer prognostic and predictive factor for antiprogestin responsiveness
title_short Progesterone receptor isoform ratio: a breast cancer prognostic and predictive factor for antiprogestin responsiveness
title_full Progesterone receptor isoform ratio: a breast cancer prognostic and predictive factor for antiprogestin responsiveness
title_fullStr Progesterone receptor isoform ratio: a breast cancer prognostic and predictive factor for antiprogestin responsiveness
title_full_unstemmed Progesterone receptor isoform ratio: a breast cancer prognostic and predictive factor for antiprogestin responsiveness
title_sort progesterone receptor isoform ratio: a breast cancer prognostic and predictive factor for antiprogestin responsiveness
publishDate 2017
url http://sedici.unlp.edu.ar/handle/10915/87477
work_keys_str_mv AT rojaspaolaa progesteronereceptorisoformratioabreastcancerprognosticandpredictivefactorforantiprogestinresponsiveness
AT maymaria progesteronereceptorisoformratioabreastcancerprognosticandpredictivefactorforantiprogestinresponsiveness
AT sequeiragonzalor progesteronereceptorisoformratioabreastcancerprognosticandpredictivefactorforantiprogestinresponsiveness
AT eliaandres progesteronereceptorisoformratioabreastcancerprognosticandpredictivefactorforantiprogestinresponsiveness
AT alvarezmichelle progesteronereceptorisoformratioabreastcancerprognosticandpredictivefactorforantiprogestinresponsiveness
AT martinezpaula progesteronereceptorisoformratioabreastcancerprognosticandpredictivefactorforantiprogestinresponsiveness
AT gonzalezpedrohoracio progesteronereceptorisoformratioabreastcancerprognosticandpredictivefactorforantiprogestinresponsiveness
AT hewittstephen progesteronereceptorisoformratioabreastcancerprognosticandpredictivefactorforantiprogestinresponsiveness
AT hexiaping progesteronereceptorisoformratioabreastcancerprognosticandpredictivefactorforantiprogestinresponsiveness
AT peroucharlesm progesteronereceptorisoformratioabreastcancerprognosticandpredictivefactorforantiprogestinresponsiveness
AT molinoloalfredo progesteronereceptorisoformratioabreastcancerprognosticandpredictivefactorforantiprogestinresponsiveness
AT gibbonsluz progesteronereceptorisoformratioabreastcancerprognosticandpredictivefactorforantiprogestinresponsiveness
AT abbamartincarlos progesteronereceptorisoformratioabreastcancerprognosticandpredictivefactorforantiprogestinresponsiveness
AT gasshugo progesteronereceptorisoformratioabreastcancerprognosticandpredictivefactorforantiprogestinresponsiveness
AT lanariclaudia progesteronereceptorisoformratioabreastcancerprognosticandpredictivefactorforantiprogestinresponsiveness
bdutipo_str Repositorios
_version_ 1764820490099097601